From the publishers of JADPRO

Bone Protection Resource Center

Advertisement

Bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone plus prednisone in the PEACE-1 phase 3 trial.

According to data from the phase 3 PEACE-1 trial, presented during the 2022 ASCO Genitourinary Cancers Symposium, of patients with de novo metastatic castration-sensitive prostate cancer, abiraterone plus prednisone combined with androgen deprivation therapy (ADT) and docetaxel is associated with a modest to no increase in bone loss across the first 2 years of therapy, compared with ADT and docetaxel alone. Researchers measured bone mineral density of the lumbar spine, femoral neck, and total hip using dual x-ray absorptiometry at baseline and months 6, 12, and 24.

2022 ASCO Genitourinary Cancers Symposium (Abstract)
Advertisement
News & Literature Highlights

Cells

Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management

Current Osteoporosis Reports

Updates in Management of Bone Metastatic Disease in Primary Solid Tumors with Systemic Therapies

JAMA Network Open

Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy

Journal of the National Comprehensive Cancer Network

Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors

Annals of Pharmacotherapy

Impact of Extended-Interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Non–Small-Cell Lung Cancer and Small-Cell Lung Cancer Patients With Bone Metastases

JAMA Open Network

Description of Major Osteoporotic Fractures in Women With Invasive Breast Cancer Who Received Endocrine Therapy

JAMA Open Network

Evaluation of Frequency of Administration of Intravenous Bisphosphonate and Recurrent Skeletal-Related Events in Patients With Multiple Myeloma

Journal of Bone Oncology

Bone Metastases From Urothelial Carcinoma. The Dark Side of the Moon

Metabolism

Effect of antiresorptive therapy on aromatase inhibitor induced bone loss in postmenopausal women with early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials

Journal of Clinical Oncology

Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update

Advertisement
Advertisement